Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study.
Publication
, Conference
Richardson, P; Soiffer, RJ; Antin, JH; Jin, Z; Vredenburgh, JJ; Kurtzberg, J; Martin, PL; Hockenbery, D; Steinbach, G; Murray, KF; Chen, A ...
Published in: BLOOD
November 16, 2003
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
193A / 193A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Richardson, P., Soiffer, R. J., Antin, J. H., Jin, Z., Vredenburgh, J. J., Kurtzberg, J., … Guinan, E. C. (2003). Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study. In BLOOD (Vol. 102, pp. 193A-193A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
Richardson, P., R. J. Soiffer, J. H. Antin, Z. Jin, J. J. Vredenburgh, J. Kurtzberg, P. L. Martin, et al. “Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study.” In BLOOD, 102:193A-193A. AMER SOC HEMATOLOGY, 2003.
Richardson P, Soiffer RJ, Antin JH, Jin Z, Vredenburgh JJ, Kurtzberg J, et al. Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 193A-193A.
Richardson, P., et al. “Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 193A-193A.
Richardson P, Soiffer RJ, Antin JH, Jin Z, Vredenburgh JJ, Kurtzberg J, Martin PL, Hockenbery D, Steinbach G, Murray KF, Vogelsang GB, Chen A, Krishnan A, Prasad VK, Warren DL, Momtaz P, Batchelder A, Wei LJ, Rifai N, Bradwin G, Iacobelli M, McDonald GB, Guinan EC. Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 193A-193A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
193A / 193A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology